CN115192580A - 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 - Google Patents
一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 Download PDFInfo
- Publication number
- CN115192580A CN115192580A CN202210356800.1A CN202210356800A CN115192580A CN 115192580 A CN115192580 A CN 115192580A CN 202210356800 A CN202210356800 A CN 202210356800A CN 115192580 A CN115192580 A CN 115192580A
- Authority
- CN
- China
- Prior art keywords
- compound
- erbb2
- pharmaceutically acceptable
- acceptable salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021103581923 | 2021-04-01 | ||
| CN202110358192 | 2021-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115192580A true CN115192580A (zh) | 2022-10-18 |
Family
ID=83458071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210356800.1A Pending CN115192580A (zh) | 2021-04-01 | 2022-03-31 | 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240197737A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4316491A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514098A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115192580A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022206929A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116606289A (zh) * | 2022-02-17 | 2023-08-18 | 上海医药集团股份有限公司 | 一种含氮杂环化合物的晶型、制备方法及应用 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| AU2024255740A1 (en) * | 2023-04-11 | 2025-10-23 | Cogent Biosciences, Inc. | Erbb2 inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101219102A (zh) * | 2007-12-11 | 2008-07-16 | 山东蓝金生物工程有限公司 | 一种治疗实体肿瘤的拉帕替尼缓释植入剂 |
| CN102731395A (zh) * | 2011-04-15 | 2012-10-17 | 中国科学院上海药物研究所 | 抗肿瘤药物来那替尼的中间体及其制备与应用 |
| CN109422755A (zh) * | 2017-09-01 | 2019-03-05 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007095038A2 (en) * | 2006-02-09 | 2007-08-23 | Novartis Ag | Mutations and polymorphisms of erbb2 |
| CN115057861A (zh) | 2016-03-01 | 2022-09-16 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| US20220143023A1 (en) * | 2019-03-29 | 2022-05-12 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
| MX2023003362A (es) * | 2020-09-23 | 2023-05-30 | Scorpion Therapeutics Inc | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. |
| WO2023155899A1 (zh) * | 2022-02-17 | 2023-08-24 | 上海医药集团股份有限公司 | 一种含氮杂环化合物的晶型、制备方法及应用 |
-
2022
- 2022-03-31 WO PCT/CN2022/084650 patent/WO2022206929A1/zh not_active Ceased
- 2022-03-31 JP JP2023560644A patent/JP2024514098A/ja active Pending
- 2022-03-31 US US18/284,162 patent/US20240197737A1/en active Pending
- 2022-03-31 CN CN202210356800.1A patent/CN115192580A/zh active Pending
- 2022-03-31 EP EP22779109.2A patent/EP4316491A4/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101219102A (zh) * | 2007-12-11 | 2008-07-16 | 山东蓝金生物工程有限公司 | 一种治疗实体肿瘤的拉帕替尼缓释植入剂 |
| CN102731395A (zh) * | 2011-04-15 | 2012-10-17 | 中国科学院上海药物研究所 | 抗肿瘤药物来那替尼的中间体及其制备与应用 |
| CN109422755A (zh) * | 2017-09-01 | 2019-03-05 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
Non-Patent Citations (1)
| Title |
|---|
| ZHONGBEN TANG,等: "Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma", FRONT ONCOL, vol. 11, 18 March 2021 (2021-03-18), pages 605658 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116606289A (zh) * | 2022-02-17 | 2023-08-18 | 上海医药集团股份有限公司 | 一种含氮杂环化合物的晶型、制备方法及应用 |
| CN116606289B (zh) * | 2022-02-17 | 2026-02-24 | 上海医药集团股份有限公司 | 一种含氮杂环化合物的晶型、制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240197737A1 (en) | 2024-06-20 |
| EP4316491A1 (en) | 2024-02-07 |
| JP2024514098A (ja) | 2024-03-28 |
| WO2022206929A1 (zh) | 2022-10-06 |
| EP4316491A4 (en) | 2025-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11291667B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| CN108137593B (zh) | 蛋白激酶抑制剂的制备和用途 | |
| JP6732906B2 (ja) | ピリミジン誘導体及びその使用 | |
| TW202136252A (zh) | 化合物及其用途 | |
| US20180325901A1 (en) | Chiral diaryl macrocycles and uses thereof | |
| WO2022206929A1 (zh) | 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 | |
| JP2010505859A (ja) | タンパク質キナーゼ阻害剤およびそれを使用するための方法 | |
| AU2021298154A1 (en) | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | |
| EA024809B1 (ru) | Замещенные соединения пиридазинкарбоксамида | |
| EP4171556A1 (en) | A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc | |
| JP2019511554A (ja) | 静止細胞標的化およびegfr阻害剤を用いた新生物の処置のための組み合わせ | |
| US20140350050A1 (en) | Pyridine compounds as inhibitors of kinase | |
| WO2017129094A1 (zh) | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 | |
| WO2019184966A1 (zh) | 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途 | |
| JP2023540491A (ja) | 突然変異型egfr阻害化合物およびその適用 | |
| TW202510857A (zh) | 化合物及其用途 | |
| CN115785107B (zh) | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 | |
| US11427559B2 (en) | Substituted quinolines useful as kinase inhibitors | |
| WO2021018017A1 (zh) | 作用于egfr和erbb2的嘧啶类化合物 | |
| HK40105285A (en) | Application of compound in preparation of inhibitory drug targeting erbb2 mutant | |
| CN112279834B (zh) | 一种fgfr4抑制剂、制备方法、药物组合物及其应用 | |
| WO2015014283A1 (zh) | 蛋白酪氨酸激酶抑制剂及其应用 | |
| WO2022184119A1 (zh) | 酪氨酸激酶抑制剂及其药物应用 | |
| WO2017049711A1 (zh) | 喹啉类衍生物、其药物组合物、制备方法及应用 | |
| CN112194652B (zh) | 4-羟甲基-1h-吲哚类化合物、制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |